Evidence map›Paper›PMID 34325054›Full record

ArticleOphthalmology. Retina2021

Cluster Analysis and Genotype-Phenotype Assessment of Geographic Atrophy in Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report 25.

Tiarnan D L Keenan, Neal L Oden, Elvira Agrón, Traci E Clemons, Alice Henning, Lars G Fritsche, Wai T Wong, Emily Y Chew, Age-Related Eye Disease Study 2 Research Group

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Ophthalmology. Retina, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Tiarnan D L KeenanDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: tiarnan.keenan@nih.gov.
Neal L OdenThe Emmes Company LLC, Rockville, Maryland.
Elvira AgrónDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Traci E ClemonsThe Emmes Company LLC, Rockville, Maryland.
Alice HenningThe Emmes Company LLC, Rockville, Maryland.
Lars G FritscheDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan.
Wai T WongJanssen Research and Development LLC, Raritan, New Jersey.
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Age-Related Eye Disease Study 2 Research Group
Emmes (United States) · USNational Institutes of Health · USJanssen (United States) · USUniversity of Michigan · US

Funding

Age-Related Eye Disease Follow-up Study (AREDS) Follow-up StudyZIAEY000489 · NEI · NATIONAL EYE INSTITUTE · PI CHEW, EMILY Y · 2009 to 2025
$639k
Intramural NIH HHS Z99 EY999999NEI NIH HHS N01 EY050007
6 · The paper itself

Abstract

purposeTo explore whether phenotypes in geographic atrophy (GA) secondary to age-related macular degeneration can be separated into 2 or more partially distinct subtypes and if these have different genetic associations. This is important because distinct GA subtypes associated with different genetic factors might require customized therapeutic approaches.

designCluster analysis of participants within a controlled clinical trial, followed by assessment of phenotype-genotype associations.

participantsAge-Related Eye Disease Study 2 participants with incident GA during study follow-up: 598 eyes of 598 participants.

methodsPhenotypic features from reading center grading of fundus photographs were subjected to cluster analysis, by k-means and hierarchical methods, in cross-sectional analyses (using 15 phenotypic features) and longitudinal analyses (using 14 phenotypic features). The identified clusters were compared by 4 pathway-based genetic risk scores (complement, extracellular matrix, lipid, and ARMS2). The analyses were repeated in reverse (clustering by genotype and comparison by phenotype).

main outcome measuresCharacteristics and quality of cluster solutions, assessed by Calinski-Harabasz scores, unexplained variance, and consistency; and genotype-phenotype associations, assessed by t test.

resultsIn cross-sectional phenotypic analyses, k-means identified 2 clusters (labeled A and B), whereas hierarchical clustering identified 4 clusters (C-F); cluster membership differed principally by GA configuration but in few other ways. In longitudinal phenotypic analyses, k-means identified 2 clusters (G and H) that differed principally by smoking status but in few other ways. These 3 sets of cluster divisions were not similar to each other (r ≤ 0.20). Despite adequate power, pairwise cluster comparison by the 4 genetic risk scores demonstrated no significant differences (P > 0.05 for all). In clustering by genotype, k-means identified 2 clusters (I and J). These differed principally at ARMS2, but no significant genotype-phenotype associations were observed (P > 0.05 for all).

conclusionsPhenotypic clustering resulted in GA subtypes defined principally by GA configuration in cross-sectional analyses, but these were not replicated in longitudinal analyses. These negative findings, together with the absence of significant phenotype-genotype associations, indicate that GA phenotypes may vary continuously across a spectrum, rather than consisting of distinct subtypes that arise from separate genetic causes.

Indexed as

AgedAged, 80 and overCluster AnalysisComplement Factor HCross-Sectional StudiesDNAFemaleFluorescein AngiographyFundus OculiGenotypeGeographic AtrophyHumansMacular DegenerationMaleMiddle AgedPhenotypeComplement Factor HDNA

Identifiers

PMID34325054
PMCPMC8578299
OpenAlexW3186942472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.